Bristol, Sanofi, Takeda gain positive CHMP recommendations
Seeking Alpha News (Fri, 26-Apr 2:32 PM ET)
PRNewswire (Fri, 26-Apr 8:02 AM ET)
DZ BANK AG Keeps Their Hold Rating on Sanofi (SNYNF)
TipRanks (Thu, 25-Apr 2:35 PM ET)
Sanofi SA Starts 2024 with Strong Sales Growth
TipRanks (Thu, 25-Apr 12:01 PM ET)
AbbVie reports positive results from Rinvoq versus Dupixent study
Seeking Alpha News (Thu, 25-Apr 11:24 AM ET)
Jefferies Sticks to Its Buy Rating for Sanofi (SNYNF)
TipRanks (Thu, 25-Apr 10:35 AM ET)
Benzinga (Thu, 25-Apr 10:15 AM ET)
Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings
Benzinga (Thu, 25-Apr 9:47 AM ET)
SNY Earnings: Sanofi Jumps on Healthy Q1 Performance
TipRanks (Thu, 25-Apr 6:47 AM ET)
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Sanofi - American Depositary Shares trades on the NASDAQ stock market under the symbol SNY.
As of April 26, 2024, SNY stock price declined to $49.33 with 2,258,376 million shares trading.
SNY has a beta of 0.83, meaning it tends to be less sensitive to market movements. SNY has a correlation of 0.14 to the broad based SPY ETF.
SNY has a market cap of $123.18 billion. This is considered a Large Cap stock.
Last quarter Sanofi - American Depositary Shares reported $11 billion in Revenue and $.97 earnings per share. This beat revenue expectation by $294 million and exceeded earnings estimates by $.03.
In the last 3 years, SNY stock traded as high as $58.10 and as low as $36.91.
The top ETF exchange traded funds that SNY belongs to (by Net Assets): FVD, GCOW, PID, PPH, PVAL.
SNY has underperformed the market in the last year with a return of -10.4%, while the SPY ETF gained +27.0%. In the last 3 month period, SNY fell short of the market, returning -1.1%, while SPY returned +4.7%. However, in the most recent 2 weeks SNY has outperformed the stock market by returning +5.9%, while SPY returned -1.7%.
SNY support price is $48.71 and resistance is $50.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNY stock will trade within this expected range on the day.